Pitt spinout BlueSphere Bio has attracted an initial $45.6m in series B funding towards a $105m target size.
BlueSphere Bio, a US-based immunotherapy spinout of University of Pittsburgh (Pitt), attracted $45.6m in series B funding last month, the Pittsburgh Business Times has reported citing a regulatory filing.
The company is targeting a $105m close and will use the capital to further develop its immunotherapy platform, called TCXpress, that is aimed at diseases such as cancer. Its lead asset aims to boost patient outcomes in bone marrow transplants.
TCXpress is based on technology developed by chief…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
